CA-LINKSYS
24.5.2022 17:02:58 CEST | Business Wire | Press release
Linksys , a global leader in home and business WiFi networking solutions, today announced two new WiFi 6 mesh systems designed to deliver peak wireless performance for all at-home needs including remote working, streaming content, multi-user gaming and more. The Linksys Hydra 6 and Linksys Atlas 6 are Linksys’ newest entry-level dual-band products in the company's family of WiFi 6 mesh systems and come at the most affordable prices to date for the brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005310/en/
“There is an increased need for wireless connectivity that can handle the influx of devices on home networks, and deliver reliable, secure and private connections,” said Alan Cohen, VP of Marketing and Head of Product at Linksys. “Our mission is to connect everyone securely and through the launch of these systems, we provide our customers with two new options for fast speed, coverage, and connectivity at an affordable price point.”
Linksys Atlas 6 – Our Most Affordable WiFi 6 Mesh System to Date
The Linksys Atlas 6 is the newest whole-home mesh system in Linksys’ portfolio of products. Speed and performance at an affordable price, the Linksys Atlas 6 is ideal for hybrid work, online gaming, 4K UHD streaming, and more. The dual-band router works best with internet service plans up to a gigabit. Each Node has three 1Gbps Ethernet LAN ports for connecting wired devices to wireless networks and provides access to 160MHz channels for superfast wireless connections.
The Linksys Atlas 6 is available in three configurations. The 1-pack supports up to 25 devices and covers ~2,000 square feet, the 2-pack supports up to 50 devices and covers ~4,000 square feet, and the 3-pack supports up to 75 devices and up to ~6,000 square feet.
Linksys Hydra 6 – Dramatically Faster, Robust, and Reliable Connectivity
The Linksys Hydra 6 delivers high-speed wireless data for up to 25 devices over 2,000 square feet. The Linksys Hydra 6 WiFi 6 dual-band mesh router delivers dramatically faster, robust, and reliable wireless connections. Ideal for super smooth 4K UHD streaming, video conferencing, online gaming, and more. The router works best with internet service plans up to a gigabit. It provides 160 MHz channels for superfast wireless connections and has four 1 GbE Ethernet ports to connect wired devices such as gaming devices, television, DVR, and more to the wireless network.
Additional Features and Benefits for the Linksys Atlas 6 and Hydra 6
- Fast to set up. Easy to manage. – The Linksys App makes it simple to set up your WiFi network and you can control and monitor your WiFi from anywhere.
- Linksys Intelligent Mesh™ Technology – Dynamically optimize speeds and maximize the use of all bands to reduce congestion, latency and buffering.
- Security and privacy you can trust – Protect your home with automatic software updates so your network is always secure and up to date. Parental controls and separate guest networks keep devices safe.
- Peace of mind – Linksys products pass 25 quality tests, are backed by a 3-year warranty, and have 24/7 tech support.
- Grow as needed – When your family, home and needs grow, your WiFi should grow with you. Add more nodes to expand coverage for stronger connection and to handle more devices as needed.
- Robust. Stable. Reliable. – Built with the Qualcomm® Immersive Home 214 Platform users can expect great connectivity throughout the home.
Availability and Imagery
The Linksys Hydra 6 will be available beginning early summer in the US for MSRP $179.99 on Linksys.com and in select retailers; global availability to follow in the second half of 2022.
The Linksys Atlas 6 will be available beginning early summer in the US for MSRP $149.99 (1-pack), $279.99 (2-pack), and $349.99 (3-pack) on Linksys.com; global availability to follow in the second half of 2022.
Images of the Atlas 6 and Hydra 6 can be found here .
About Linksys
At Linksys, we strive to build the world’s most reliable, innovative, future-ready wireless technologies that can securely connect every person and everything, effortlessly. Founded in 1988, Linksys has since established itself as a premier networking brand. Today, Linksys hardware products, software, and services are sold in 64 countries worldwide, ranging from home routers and mesh systems to business access points and switches. Recently, Linksys expanded into education and enterprise through its partnership with Fortinet, the leader in enterprise-grade security. Linksys. For every connection.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Immersive Home 214 Platform is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005310/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom